Clinical Trial

Efficacy of Carminal in Helicobacter Pylori Gastritis

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 17, 2025 (before its estimated August 3, 2026 completion). Its status may not reflect the trial's current state.
Summary
Eighty patients will be included and randomized in two groups, one group (40 patients) will be administered 30 ml of the supplement Carminal, once a day, plus therapy for HP gastitis and the control group (40 patients) will be given standard therapy for HP gastritis with placebo. Treatment will begin after complection of upper endoscopy with histology results from biopted gastric mucosa. Treatment with Carminal will be continued after successful HP eradication during 12 weeks. The final evaluation will take place 12 weeks after the last Carminal intake, when control endoscopy with histology will be performed. The study will last approximately 24 weeks.
Trial Details
NCT Number NCT07179237
Lead Sponsor Catalysis SL
Conditions H Pylori Gastritis, H Pylori Infection, H Pylori Eradication, Gastritis Associated With Helicobacter Pylori, Gastric Mucosal Lesion
Enrollment 80 participants
Start Date 2025-08-04
Primary Completion 2026-08-03 (estimated)
Study Completion 2026-10-05 (estimated)
Updated on ClinicalTrials.gov 2025-09-17